Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | LIPE | Q05469 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22583033 | 1.00 | KMT2A (0.37) | KMT2AMEN1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL22583237 | 0.85 | SMN1; SMN2 (0.40) | KMT2AMEN1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL22583484 | 0.83 | ALDH1A1 (0.39) | KMT2AMEN1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL29601868 | 0.83 | ALDH1A1 (0.39) | KMT2AMEN1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL22583431 | 0.81 | BACE1 (0.34) | KMT2AMEN1LIPEABL1CACNA1G | |
| SCHEMBL29435649 | 0.81 | BACE1 (0.34) | KMT2AMEN1LIPEABL1CACNA1G | |
| SCHEMBL29435524 | 0.76 | ALDH1A1 (0.41) | KMT2AMEN1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL22583372 | 0.76 | ALDH1A1 (0.41) | KMT2AMEN1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL22583020 | 0.76 | ALDH1A1 (0.38) | KMT2AMEN1ALDH1A1KDM4EMAPK1 | |
| SCHEMBL29435611 | 0.76 | ALDH1A1 (0.43) | KMT2AMEN1SMN1; SMN2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276967-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | SIGNAL PHARMACEUTICALS, LLC | 2025-09-04 | — | — | US | disclosed |
| US-12338235-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CELGENE CORPORATION (US) | 2025-06-24 | — | — | US | disclosed |
| US-11505548-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CELGENE CORPORATION (US) | 2022-11-22 | — | — | US | disclosed |
| EP-3959207-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | Celgene Corporation (US) | 2022-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276967-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CYP8B1, HAX1, HRH4 | KMT2A 3502/4885MEN1 2158/4885SMN1; SMN2 668/4885 |
| US-11505548-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CYP8B1, HAX1, HRH4 | KMT2A 3502/4885MEN1 2158/4885SMN1; SMN2 668/4885 |
| US-12338235-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CYP8B1, HAX1, HRH4 | KMT2A 3502/4885MEN1 2158/4885SMN1; SMN2 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.